Menu Search
Equities

Euroapi SA

EAPI:PAR

Euroapi SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.52
  • Today's Change0.104 / 3.04%
  • Shares traded79.32k
  • 1 Year change-34.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Euroapi SA had net income fall 1,156.95% from a loss of 15.10m to a larger loss of 189.80m despite a 3.87% increase in revenues from 980.90m to 1.02bn. An increase in the cost of goods sold as a percentage of sales from 81.97% to 83.85% was a component in the falling net income despite rising revenues.
Gross margin17.04%
Net profit margin-29.58%
Operating margin-29.21%
Return on assets-15.69%
Return on equity-27.59%
Return on investment-23.68%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Euroapi SA fell by 40.00m. Cash Flow from Financing totalled 92.20m or 9.05% of revenues. In addition the company generated 5.10m in cash from operations while cash used for investing totalled 137.30m.
Cash flow per share-2.31
Price/Cash flow per share--
Book value per share9.34
Tangible book value per share8.88
More ▼

Balance sheet in EURView more

Euroapi SA has a Debt to Total Capital ratio of 34.64%, a higher figure than the previous year's 1.32%.
Current ratio1.57
Quick ratio0.7027
Total debt/total equity0.530
Total debt/total capital0.3464
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -1,157.92%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-1,042.97
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.